172 related articles for article (PubMed ID: 34136892)
1. Establishment of a 3D model of tumor-driven angiogenesis to study the effects of anti-angiogenic drugs on pericyte recruitment.
Qiu Y; Wang N; Guo T; Liu S; Tang X; Zhong Z; Chen Q; Wu H; Li X; Wang J; Zhang S; Ou Y; Wang B; Ma K; Gu W; Cao J; Chen H; Duan Y
Biomater Sci; 2021 Sep; 9(18):6064-6085. PubMed ID: 34136892
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle Delivery of MnO
Chang CC; Dinh TK; Lee YA; Wang FN; Sung YC; Yu PL; Chiu SC; Shih YC; Wu CY; Huang YD; Wang J; Lu TT; Wan D; Chen Y
ACS Appl Mater Interfaces; 2020 Oct; 12(40):44407-44419. PubMed ID: 32865389
[TBL] [Abstract][Full Text] [Related]
3. Pericytes and vessel maturation during tumor angiogenesis and metastasis.
Raza A; Franklin MJ; Dudek AZ
Am J Hematol; 2010 Aug; 85(8):593-8. PubMed ID: 20540157
[TBL] [Abstract][Full Text] [Related]
4. The epigallocatechin gallate derivative Y
Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
[TBL] [Abstract][Full Text] [Related]
5. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis.
Guan YY; Luan X; Xu JR; Liu YR; Lu Q; Wang C; Liu HJ; Gao YG; Chen HZ; Fang C
Biomaterials; 2014 Mar; 35(9):3060-70. PubMed ID: 24393268
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies.
Yao C; Wu S; Kong J; Sun Y; Bai Y; Zhu R; Li Z; Sun W; Zheng L
Cancer Biol Med; 2023 Jan; 20(1):25-43. PubMed ID: 36647777
[TBL] [Abstract][Full Text] [Related]
8. The antiangiogenic 16K prolactin impairs functional tumor neovascularization by inhibiting vessel maturation.
Nguyen NQ; Castermans K; Berndt S; Herkenne S; Tabruyn SP; Blacher S; Lion M; Noel A; Martial JA; Struman I
PLoS One; 2011; 6(11):e27318. PubMed ID: 22087289
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials of antiangiogenic therapy for hepatocellular carcinoma.
Taketomi A
Int J Clin Oncol; 2016 Apr; 21(2):213-218. PubMed ID: 26899258
[TBL] [Abstract][Full Text] [Related]
10. Role of pericytes in angiogenesis: focus on cancer angiogenesis and anti-angiogenic therapy.
Chen Z; Xu XH; Hu J
Neoplasma; 2016; 63(2):173-82. PubMed ID: 26774138
[TBL] [Abstract][Full Text] [Related]
11. New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects.
Huang M; Lin Y; Wang C; Deng L; Chen M; Assaraf YG; Chen ZS; Ye W; Zhang D
Drug Resist Updat; 2022 Sep; 64():100849. PubMed ID: 35842983
[TBL] [Abstract][Full Text] [Related]
12. Arid1a regulates response to anti-angiogenic therapy in advanced hepatocellular carcinoma.
Hu C; Li W; Tian F; Jiang K; Liu X; Cen J; He Q; Qiu Z; Kienast Y; Wang Z; Zhang H; Ji Y; Hu J; Hui L
J Hepatol; 2018 Mar; 68(3):465-475. PubMed ID: 29113912
[TBL] [Abstract][Full Text] [Related]
13. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
14. Targeting pericytes for angiogenic therapies.
Kelly-Goss MR; Sweat RS; Stapor PC; Peirce SM; Murfee WL
Microcirculation; 2014 May; 21(4):345-57. PubMed ID: 24267154
[TBL] [Abstract][Full Text] [Related]
15. New strategy of antiangiogenic therapy for hepatocellular carcinoma.
Wu XZ
Neoplasma; 2008; 55(6):472-81. PubMed ID: 18999874
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
Bono AV; Pannellini T; Liberatore M; Montironi R; Cunico SC; Cheng L; Sasso F; Musiani P; Iezzi M
Anal Quant Cytol Histol; 2010 Jun; 32(3):136-45. PubMed ID: 20701066
[TBL] [Abstract][Full Text] [Related]
17. Biologic effects of dopamine on tumor vasculature in ovarian carcinoma.
Moreno-Smith M; Lee SJ; Lu C; Nagaraja AS; He G; Rupaimoole R; Han HD; Jennings NB; Roh JW; Nishimura M; Kang Y; Allen JK; Armaiz GN; Matsuo K; Shahzad MM; Bottsford-Miller J; Langley RR; Cole SW; Lutgendorf SK; Siddik ZH; Sood AK
Neoplasia; 2013 May; 15(5):502-10. PubMed ID: 23633922
[TBL] [Abstract][Full Text] [Related]
18. Weibel-Palade Bodies Orchestrate Pericytes During Angiogenesis.
Cossutta M; Darche M; Carpentier G; Houppe C; Ponzo M; Raineri F; Vallée B; Gilles ME; Villain D; Picard E; Casari C; Denis C; Paques M; Courty J; Cascone I
Arterioscler Thromb Vasc Biol; 2019 Sep; 39(9):1843-1858. PubMed ID: 31315435
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
Pang R; Poon RT
Cancer Lett; 2006 Oct; 242(2):151-67. PubMed ID: 16564617
[TBL] [Abstract][Full Text] [Related]
20. VEGFR2-dependent angiogenic capacity of pericyte-like dental pulp stem cells.
Janebodin K; Zeng Y; Buranaphatthana W; Ieronimakis N; Reyes M
J Dent Res; 2013 Jun; 92(6):524-31. PubMed ID: 23609159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
